Horizon still has a mountain to climb
But positive mid-stage Sjögren’s data raise hopes for others still plugging away at anti-CD40 assets.
Viridian takes on Horizon
Early data in thyroid eye disease impress, but unanswered questions include the size of the market.
Go or no go? FDA firsts for Imfinzi, Enhertu and roflumilast
Assets in oncology and psoriasis are set for upcoming Pdufa decisions.
In a quiet year for takeouts, who was buying?
Small and mid-sized developers upped deal-making activity last year, a deep dive into M&A data finds.
Biopharma’s stock market winners of 2021 revealed
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.
What Novartis could buy with its windfall
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
Novartis pushes on with iscalimab after transplant disappointment
The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.
Fortunes diverge for solo drug launchers
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
